Storia della carriera di Colin Scott
Precedenti posizioni note di Colin Scott
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| NOVABAY PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2006 | 31/12/2008 |
| GLYCOMIMETICS, INC. | Corporate Officer/Principal | 01/10/2004 | 01/12/2005 |
Arriva Pharmaceuticals, Inc.
 Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Direttore Tecnico/Scientifico/R&S | 01/09/2002 | 01/05/2004 |
| Consigliere Generale | 01/09/2002 | 01/05/2004 | |
| EMISPHERE TECHNOLOGIES, INC. | Direttore Tecnico/Scientifico/R&S | 01/03/2001 | 01/05/2002 |
Formazione di Colin Scott
| University of Glasgow | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
| Regno Unito | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 1 |
| General Counsel | 1 |
Settori
| Health Technology | 5 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| NOVABAY PHARMACEUTICALS, INC. | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Health Technology |
Emisphere Technologies, Inc.
 Emisphere Technologies, Inc. Pharmaceuticals: MajorHealth Technology Emisphere Technologies, Inc. is a commercial stage specialty pharmaceutical company, which engages in the development of new formulations of existing products and chemical entities, using Eligen Technology. Its product pipelines include eligen B12, eligen12.com, eligen B12 information, and purchase eligen B12. The company was founded in 1986 and is headquartered in Roseland, NJ. | Health Technology |
- Borsa valori
- Insiders
- Colin Scott
- Esperienza
